Abstract
Twenty-three patients with acute myelocytic leukemia (aml) were treated with daunomycin and the results contrasted to those obtained in a subsequent group of 18 patients treated with cytosine arabinoside (ara-c) and 6-thioguanine (tg). The complete remission (cr) rate with daunomycin was 17 percent (mean duration 10.6 months) and the partial remission (pr) rate 26 percent (mean duration 44 days). Corresponding figures in the ara-c and tg group were: cr rate 44 percent (mean duration 5.8 months) and pr rate 17 percent (mean duration 48 days).
There were 12 deaths resulting from daunomycin-induced pancytopenia and in ten of the patients who died persistent leukemia infiltrate was found in antemortem marrow specimens or at autopsy. This contrasts with death of six patients from ara-c and tg-induced pancytopenia, in four of whom residual leukemic infiltrate was not evident.
Daunomycin alone is deemed not suitable for induction of remission in aml. The results obtained with ara-c and tg are encouraging and may be improved if the number of infectious deaths associated with drug-induced pancytopenia can be reduced.
Full text
PDFSelected References
These references are in PubMed. This may not be the complete list of references from this article.
- Alberts D. S., Bachur N. R., Holtzman J. L. The pharmacokinetics of daunomycin in man. Clin Pharmacol Ther. 1971 Jan-Feb;12(1):96–104. doi: 10.1002/cpt197112196. [DOI] [PubMed] [Google Scholar]
- Bodey G. P., Buckley M., Sathe Y. S., Freireich E. J. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med. 1966 Feb;64(2):328–340. doi: 10.7326/0003-4819-64-2-328. [DOI] [PubMed] [Google Scholar]
- Bodey G. P., Rodriguez V., Hart J., Freireich E. J. Therapy of acute leukemia with the combination of cytosine arabinoside (NSC-63878) and cyclophosphamide (NSC-26271). Cancer Chemother Rep. 1970 Aug;54(4):255–262. [PubMed] [Google Scholar]
- Boiron M., Weil M., Jacquillat C., Tanzer J., Levy D., Sultan C., Bernard J. Daunorubicin in the treatment of acute myelocytic leukaemia. Lancet. 1969 Feb 15;1(7590):330–333. doi: 10.1016/s0140-6736(69)91296-3. [DOI] [PubMed] [Google Scholar]
- Crowther D., Bateman C. J., Vartan C. P., Whitehouse J. M., Malpas J. S., Fairley G. H., Scott R. B. Combination chemotherapy using L-asparaginase, daunorubicin, and cytosine arabinoside in adults with acute myelogenous leukaemia. Br Med J. 1970 Nov 28;4(5734):513–517. doi: 10.1136/bmj.4.5734.513. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ellison R. R., Holland J. F., Weil M., Jacquillat C., Boiron M., Bernard J., Sawitsky A., Rosner F., Gussoff B., Silver R. T. Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults. Blood. 1968 Oct;32(4):507–523. [PubMed] [Google Scholar]
- Gee T. S., Yu K. P., Clarkson B. D. Treatment of adult acute leukemia with arabinosylcytosine and thioguanine. Cancer. 1969 May;23(5):1019–1032. doi: 10.1002/1097-0142(196905)23:5<1019::aid-cncr2820230506>3.0.co;2-n. [DOI] [PubMed] [Google Scholar]
- HEWLETT J. S., BATTLE J. D., Jr, BISHOP R. C., FOWLER W. M., SCHWARTZ S. O., HAGEN P. S., LOUIS J. PHASE II STUDY OF A-8103 (NSC-25154) IN ACUTE LEUKEMIA IN ADULTS. Cancer Chemother Rep. 1964 Nov;42:25–28. [PubMed] [Google Scholar]
- Henderson E. S. Treatment of acute leukemia. Ann Intern Med. 1968 Sep;69(3):628–632. doi: 10.7326/0003-4819-69-3-628. [DOI] [PubMed] [Google Scholar]
- Tan C., Tasaka H., Yu K. P., Murphy M. L., Karnofsky D. A. Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia. Cancer. 1967 Mar;20(3):333–353. doi: 10.1002/1097-0142(1967)20:3<333::aid-cncr2820200302>3.0.co;2-k. [DOI] [PubMed] [Google Scholar]
- Theologides A., Yarbro J. W., Kennedy B. J. Daunomycin inhibition of DNA and RNA synthesis. Cancer. 1968 Jan;21(1):16–21. doi: 10.1002/1097-0142(196801)21:1<16::aid-cncr2820210104>3.0.co;2-4. [DOI] [PubMed] [Google Scholar]
- Wiernik P. H., Serpick A. A. Factors effecting remission and survival in adult acute nonlymphocytic leukemia (ANLL). Medicine (Baltimore) 1970 Nov;49(6):505–513. doi: 10.1097/00005792-197011000-00004. [DOI] [PubMed] [Google Scholar]